Black Diamond Therapeutics, Inc. cotiza a 1.68 USD y tiene una capitalización bursátil de $97M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Pha…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.17 | $-0.16 | $-0.14 |
| Estimado | $-0.03 | $-0.20 | $-0.21 | $-0.17 |
| Sorpresa | — | +15.0% | +23.8% | +17.6% |
| Métrica | BDTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | 17.9% | -38.6% | +56.5% |
| Net Margin | 31.9% | -33.6% | +65.5% |
| FCF Margin | — | -13.9% | — |
| ROE | 19.9% | -40.4% | +60.3% |
| ROA | 15.6% | -32.0% | +47.6% |
| Current Ratio | 8.42 | 2.84 | +5.58 |
| Debt / Equity | — | 0.28 | — |